These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27128217)

  • 1. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
    Barve A; Kovacs SJ; Ke J; Crabbe R; Grosgurin P; Menetrey A; Nicolas-Métral V; Dabovic K; Dole K; Zhang J; Praestgaard J; Sunkara G; Stein D
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):25-32. PubMed ID: 27128001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
    Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
    Moore K; Infante JR; Cotreau MM; Wilson L; Strahs AL; Vargo DL; Chadha M
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):284-9. PubMed ID: 27128834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
    Abbas R; Boni J; Sonnichsen D
    Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
    Mayer EL; Scheulen ME; Beckman J; Richly H; Duarte A; Cotreau MM; Strahs AL; Agarwal S; Steelman L; Winer EP; Dickler MN
    Breast Cancer Res Treat; 2013 Jul; 140(2):331-9. PubMed ID: 23868188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.
    Wang H; Yang Y; Chen Z; Fu L; Yu M; Jiang L; Wang C; Men L; Minto I; Yang D; Zhai Y
    Clin Transl Sci; 2024 Sep; 17(9):e70021. PubMed ID: 39228016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J; Kankam M; Trone D; Gammon G
    Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
    Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT
    J Clin Pharmacol; 2015 Dec; 55(12):1378-85. PubMed ID: 26053962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.